Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Johnson and Johnson
Mallinckrodt
AstraZeneca

Last Updated: August 13, 2022

CLINICAL TRIALS PROFILE FOR TRIHEPTANOIN


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Triheptanoin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00328159 ↗ Nutritional Therapy of the Deficits of Oxidation Mitochondrial of the Fatty Acids Completed Assistance Publique - Hôpitaux de Paris N/A 2006-06-01 Usual dietary therapies of mitochondrial fatty acid oxidation disorders (FAO) are based on 3 strategies: - limitation of lipid intake in the diet; - supplementation of the diet with medium-chain triglycerides (MCT) for patients affected with disorders of long-chain FAO; - some specific supplementations (for example, L-carnitine). These strategies are often ineffective. The aim of the present study is to evaluate new therapeutic ways based on the underlying energetic defect observed in these disorders. The long-term goal is to develop efficient therapies of these disorders.
NCT00947960 ↗ Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease Completed Ultragenyx Pharmaceutical Inc Phase 2 2009-06-01 The purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease.
NCT00947960 ↗ Triheptanoin Treatment Trial for Patients With Adult Polyglucosan Body Disease Completed Baylor Research Institute Phase 2 2009-06-01 The purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of Adult Polyglucosan Body Disease.
NCT00983788 ↗ Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects Completed Groupe Hospitalier Pitie-Salpetriere Phase 2 2009-10-01 The investigators propose to evaluate the effect of bezafibrate on metabolism during exercise in 22 adult patients affected with carnitine palmitoyltransferase II (CPTII) or very-long chain acyl-CoA-dehydrogenase (VLCAD) deficiencies. This study will be an 9-month, randomized, double-blind, placebo-controlled crossover trial. The trial will be conducted in two centers: Institut de Myologie, Pitié-Salpêtrière Hospital in France, and Rigshospitalet, University of Copenhagen, in Denmark. The main criteria for assessing the potential effect of this drug will be the fat oxidation rate studied during a moderate workload on cycle ergometer, after infusion of stable isotopes (palmitate and glucose tracers).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Triheptanoin

Condition Name

Condition Name for Triheptanoin
Intervention Trials
Glucose Transporter Type 1 Deficiency Syndrome 7
Glut1 Deficiency Syndrome 4
GLUT1DS1 3
Glut1 Deficiency Syndrome 1, Autosomal Recessive 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Triheptanoin
Intervention Trials
Syndrome 12
Carbohydrate Metabolism, Inborn Errors 11
Glycogen Storage Disease 5
Metabolic Diseases 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Triheptanoin

Trials by Country

Trials by Country for Triheptanoin
Location Trials
United States 48
France 7
United Kingdom 5
Spain 4
Denmark 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Triheptanoin
Location Trials
Texas 10
Pennsylvania 6
Florida 5
Washington 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Triheptanoin

Clinical Trial Phase

Clinical Trial Phase for Triheptanoin
Clinical Trial Phase Trials
Phase 3 2
Phase 2 17
Phase 1/Phase 2 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Triheptanoin
Clinical Trial Phase Trials
Completed 15
No longer available 4
Unknown status 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Triheptanoin

Sponsor Name

Sponsor Name for Triheptanoin
Sponsor Trials
Ultragenyx Pharmaceutical Inc 17
University of Texas Southwestern Medical Center 5
Institut National de la Santé Et de la Recherche Médicale, France 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Triheptanoin
Sponsor Trials
Other 40
Industry 17
NIH 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
Baxter
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.